Clinical Trial Update: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate [Phase 4]

View source ↗

Summary

Phase 4 study comparing certolizumab pegol plus methotrexate to adalimumab plus methotrexate in patients with moderate-to-severe rheumatoid arthritis inadequate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• CIMZIA (CERTOLIZUMAB PEGOL)
• Humira (adalimumab)

Snippet

Sponsor: UCB Pharma SA | Conditions: Rheumatoid Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2017-03-31